DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Hemodynamic Effects of Chronic Administration of Spironolactone and/or Propranolol in Alcoholic Cirrhotic Patients

Information source: University Hospital, Angers
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Alcoholic Cirrhosis

Intervention: Propranolol - Spironolactone (Drug)

Phase: Phase 4

Status: Terminated

Sponsored by: University Hospital, Angers

Official(s) and/or principal investigator(s):
Paul Cales, PHD, Principal Investigator, Affiliation: UH Angers


The aim of this study was assesment of splanchnic and systemic hemodynamic effects of chronic administration (2 month) of spironolactone or propranolol, alone or in association in alcoholic cirrhotic patients. The patients were randomized in 4 groups (aldactone 150 mg/day, propranolol 160 mg/day, aldactone 150 mg/day + propranolol 160 mg/day, placebo). Systemic and splanchnic hemodynamic effect were evaluated by hepatic venous pressure gradient measurements before and after 2 month of treatment.

Clinical Details

Official title: Hemodynamic Effects of Chronic Administration of Spironolactone, Propranolol and Their Association in Alcoholic Cirrhotic Patients

Study design: Allocation: Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Parallel Assignment, Masking: Double-Blind, Primary Purpose: Prevention

Primary outcome: assessment of hepatic veinous pressure gradient changes after chronic treatment by spironolactone or propranolol alone or in association.

Secondary outcome: Efficacy of spironolactone/propranolol association


Minimum age: 18 Years. Maximum age: 75 Years. Gender(s): Both.


Inclusion Criteria:

- Indication of transjugular hepatic biopsy

- alcoholic cirrhosis

- presence of oesophageal varices ≤ stade 2

Exclusion Criteria:

- renal insufficiency

- natremia ≤ 135 mmol/l

- vasoactive treatment in the last month before inclusion

- hepatocellular carcinoma

- positive HIV and HCV patients

- paracentesis in the last week before inclusion

- digestive bleeding in one last week

- oesophageal varices stade 3 or 2 with red signs

Locations and Contacts

Additional Information

Starting date: April 1995
Last updated: December 28, 2005

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017